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Selective trophic effect of L-carnitine in type I and ha skeletal muscle
fibers. Biopsies were taken from the vastus lateralis muscle of 26 chronic
uremic patients before and after a 24-week treatment with L-carnitine
given at the dose of 2 g i.v. at the end of hemodialysis, or in dialysis
solution, or per os twice daily. The aim of the study was to evaluate both
the muscle morphology in dialyzed subjects and the modification provoked
by the therapy. All patients manifested a significant, even if variable,
degree of muscular atrophy which involved all types of muscle fibers. After
the treatment there was an increase of about 7% in the diameter of type
I and type ha fibers, which can utilize carnitine for fatty acid oxidation to
produce energy, and a reduction in the atrophic fibers. No noteworthy
changes were documented in type JIb fibers, which depend on glycolysis
for energy production.
L-carnitine, a quaternary amine, is a natural constituent of cells
that plays a fundamental role in skeletal muscle metabolism by
promoting mitochondrial oxidation of fatty acids [1—3]. It is mainly
utilized by type I and IIa muscle fibers, which have a wide range
of oxidative enzymes, whereas type IIb fibers are characteristically
anaerobic and, therefore, do not generally use fatty acids and, in
consequence, carnitine for metabolism [4—6].
Patients on chronic hemodialysis are reported to be deficient in
carnitine [7, 8], probably due to the hemodialysis membrane being
permeable to low molecular weight compounds [9]. Lack of
carnitine causes atrophy in type I and ha muscle fibers, and is
associated with an accumulation of intracytoplasmic lipids [4, 5,
10]. Diffuse fiber atrophy, not directly correlated with carnitine
deficiency, which is often more marked in type II fibers, has also
been observed in uremic patients [11, 12].
It has been demonstrated that hemodialysis patients treated
with 2 g/i.v./day L-carnitine for one year present type I fiber
predominance and hypertrophy, while the type II fibers remain
unaltered, and that the hypertrophy regresses markedly four
months after the therapy is suspended [13].
We carried out a prospective study to determine whether
L-carnitine supplementation was able to increase muscle carnitine
levels, reduce muscle hypotrophy and improve muscle strength in
patients on maintenance hemodialysis.
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Methods
Patients
Twenty-six patients who had been on maintenance hemodialytic
treatment for at least one year (range 1 to 14 years) were enrolled
in the study.
On enrollment, all patients had a GFR C 1 mI/mm and both
their nutritional and hematological conditions were satisfactory.
Table 1 details the patient data.
Exclusion criteria were: malignancies, liver failure, severe hy-
pertension, concomitant diseases affecting the skeletal muscle
function, and treatment with anabolistic compounds and/or L-
carnitine during the six months preceding the study.
Patients were divided into three groups on the basis of three
different regimens of carnitine supplementation procedures.
Group 1. Eleven patients (7 males, 4 females, mean age 55.5
years) had 0.0725 mM/liter (2 g in 170 liter) added directly to the
dialytic solution.
Group 2. Six patients (4 males, 2 females, mean age 50.9 years)
were administered 2 g L-camitine per os daily.
Group 3. Nine patients (6 males, 3 females, mean age 54.8
years) were given 2 g L-carnitine i.v. at the end of each dialytic
treatment.
L-carnitine doses, supplemented for 24 weeks in all cases, were
comparable.
Moiphometty
Muscle biopsies were obtained from the upper-third of the
musculus vastus lateralis of the femoral quadriceps at basal time
and after 24 weeks.
Biopsies were snap frozen in isopenthane brought to freezing
point in liquid nitrogen and sectioned in a cryostat. Sections were
stained by the ATPase technique at pH 9.4, 4.6 and 4.3 to
distinguish the various types of fiber and by the Red-O oil method
to visualize intracytoplasmic lipids.
Morphometric analysis was performed with a Leitz MIAIvIED
image analyzer. MODE (Leica) software was used for determin-
ing: (1) the number and percentage of type I and type II fibers; (2)
the mean lesser diameters of fibers in transverse section; (3)
atrophy and hypertrophy factors, respectively indicative of the
proportion of fibers with a diameter of less than 40 t in men and
30 g in women and the proportion of fibers with a diameter
greater than 80 ji in men and 70 g in women. The atrophy factor
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Table 1. Patient and hemodialytic data
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Men 17
Women 9
Mean age years 55.3
Serum creatinine mg/mI 13.2
Mean dialytic time months 71
Dialysis treatment mm 240
Blood flow rate mI/mm 272
Dialyzer surface area m2 1—1.7
Heparin U/dialysis 7500 1500
Dialysate acetate mml/liter 17
Dialysate bicarbonate g/liter 9
is derived, in men, by multiplying the number of fibers with a
diameter between 30 and 40 (20 to 30 in women) by one, the
number of fibers with a diameter between 20 and 30 ,tt (10 to 20
in women) by two, the number of those from 10 and 20 j.t (< 10
.t in women) by three, and the number of those with a diameter
less than 10 by four. These products are added together, divided
by the total number of computed fibers and then multiplied by
1000. Hypertrophy factor is computed dividing the number of
fibers with a diameter larger than 80 (70 j.t in women) by the
total number of computed fibers and multiplying the result by
1000 [4].
Morphometric analysis was performed "blindly", without
knowledge of group of treatment nor time of biopsy.
The overall morphometric features were evaluated in all sub-
jects irrespective of the type of treatment.
Muscle strength
The force produced by isometric contractions of the quadriceps
muscle was studied during maximal voluntary contraction, accord-
ing to the method of Edwards et al [14], which allows the isometric
strength value to be measured in kg. A force/time curve of the
isometric strength course that reflects the performance effort was
then constructed. The resulting graph allows certain fiber depen-
dant (I, ha, JIb) force features (rapid, maximal, resistant) and
their predominant metabolism (aerobic, anaerobic and mixed) to
be identified.
The first value obtained is the ascending velocity of the curve in
the first second of the effort (AP), which expresses the rapid force
of type II fibers.
The maximum isometric force peak (MIFP) value, which
expresses the maximal voluntary force involving both type of
fibers, follows.
The final value, the plateau phase (PP), is the curve length
between the MIFP and the relaxing phase. This section of the
curve represents the resistant force typical of type I aerobic fibers.
Plasma and muscle carnitine
Plasma levels of free carnitine were determined at basal time
and every four weeks up to week 24 immediately before and after
the dialytic treatment.
Muscle total carnitine, free carnitine and acetylcarnitine were
assayed before and after treatment by the method described by
McGarry and Foster [15], and Pande and Caramancion [16].
Clinical symptoms and safely
Muscle related symptoms and general clinical symptoms were
checked weekly. Standard safety laboratory tests and ECGs were
performed at basal time and at the end of the study.
Statistic
The Student's t-test for paired data was used for assessing the
mean diameters of muscle fibers before and after treatment and to
evaluate the difference of muscle and plasmatic carnitine levels
before and after treatment. The Wilcoxon's signed rank test was
used for comparing the proportion of type JIb atrophic muscle
fibers separately with type I and ha atrophic muscle fibers.
Results
Plasma and muscle carnitine
Free plasma carnitine (Fig. 1) was increased, after treatment, in
all groups. The variations were from 24.2 8.9 mM/liter to 38.0
11.0 mM/liter in group 1 (P < 0.004); from 19.2 5.6 mM/liter to
61.5 22.9 mM/liter in group 2 (P < 0.001) and from 28.0 11.8
mM/liter to 76.6 31.7 mM/liter in group 3 (P < 0.001).
Free muscle carnitine (Fig. 2) followed a similar trend. It
increased from 20.7 7.4 mai/g to 27.2 8.9 mM/g in group 1 (P
<0.05); from 18.4 4.8 mM/g to 32.2 4.3 mM/g in group 2 (P
Fig. 2. Free muscle carnitine before and after L-camitine treatment. Sym-
bols are: () basal; (0) 24th week.
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<0.001) and from 21.4 3.6 mM/g to 39.6 15.2 mM/g in group
3 (P < 0.003).
The trend of total and acetylate muscle carnitine variations was
similar to free muscle carnitine.
Although muscle and free plasma carnitine was higher in group
3 subjects, there was no statistically significant difference between
groups.
Muscle morphometiy
As free plasma and muscle carnitine levels rose markedly,
without significant intergroup differences, the morphometric re-
suits were evaluated taking the 26 patients as a single group.
Muscle fiber composition. There was no statistical difference in
the proportion of single types of muscle fiber before and after
treatment.
The percentage of muscle fibers before and after therapy were
48.3% 9.3 versus 50.5% 7.8 for type I fibers, 29.4% 8.9
versus 30,1% 9.1 for type ha fibers and 22.1% 8.8 versus
19.3% 6.5 for type JIb fibers.
Diameter of muscle fibers. Mean diameter values after treatment
were significantly greater in both sexes than pre-therapy values in
type I and ha (P < 0.001), but not in type lib fibers.
The before and after L-carnitine mean lesser diameters were
47.2 13.8 and 50.1 j. 12.1 for type I fibers, 52.6 s 14.4 and
56.2 13.9 for type ha, 48.1 j.t 14.4 and 47.8 .t 14.4 for type
JIb fibers (Fig. 3).
Atrophic muscle fibers. Dubowitz [4] defines as atrophic those
fibers that have a diameter of less than 40 in men and 30 t in
women. Numerous atrophic fibers were present in patients'
biopsies. However, the percentage of atrophic type I fibers fell
after therapy from 22.0% to 10.5% and type ha from 15.3% to
9.1%, while no noteworthy change was recorded in type hlb fibers
(from 22.8% to 20.7%; Table 2).
The atrophic factor calculated for the different types of fiber
decreased after treatment from 251.4 to 133.2 for type I, from
153.2 to 96.3 for type ha and varied from 241.2 to 257.1 for type
JIb fibers.
Because the modification in type lib fibers, which are not
equipped with enzymes that utilize carnitine, was negligible, they
acted as an internal control group for statistical evaluation.
Statistical analysis showed that the reduction in the proportion
of atrophic fibers was significant for type I fibers (P < 0.025) and
at the limits of significance for type ha fibers (P < 0.07).
Hypertrophic muscle fibers. Hypertrophic fibers are, according to
Dubowitz [4], those with a diameter greater than 80 .t and 70 in
women. Although some hypertrophic muscle fibers were found in
patients' biopsies, the proportion was negligible and there were no
significant differences between the first and second biopsies.
Muscle strength
The basal values of the isometric force (AP, MIFP, PP) were in
the low normal range or significantly below the normal range in all
the patients, according to the model of force measurement
proposed by Edwards et al [14]. After treatment there was an
increase for AP, MIFP and PP in all patients compared to the
basal values.
Paired comparison within each treatment group showed a
significant increase of isometric force values in group 1 (P < 0.04)
and in group 3 (P < 0.001).
Detailed analysis of isometric force parameters will be referred
in another paper [17].
Clinical symptoms and safeiy
Muscle strength improved in 7 patients out of 16; muscle pain
regressed in 2 out of 5 and muscle cramps in 6 out of 10.
Neither the laboratory tests nor the ECGs revealed any signif-
icant difference between the basal and end of treatment values.
Discussion
Several interesting findings emerge from this study.
All groups of dialyzed patients had significant, even if variable,
muscular atrophy.
Various muscular alteration patterns have been documented in
patients on chronic hemodialysis. Muscle morphology character-
ized by carnitine deficiency, that is, type I fiber atrophy associated
with an intracytoplasmic accumulation of lipids, has rarely been
seen even when muscle carnitine dropped to 50% of the normal
value [18, 19]. Diffuse muscular atrophy is more frequent and
particularly evident in type II fibers, probably due to secondary
hyperparathyroidism or intracellular acidosis [5, 11, 12].
However, our patients manifested no significant difference in
the percent of the various types of atrophic fibers (type I, 22.0%;
type ha, 15.3%; type lIb, 22.8%) and there was no evidence of
intracytoplasmic lipid accumulation.
Muscular atrophy seems, therefore, not to be associated with a
carnitine deficiency.
Despite the fact that no patient presented a pathologically low
carnitine level, administration of L-carnitine determined a
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Table 2. Variability of atrophic, normal and hypertrophic fibers before
and after L-carnitine treatment
Type I
Normal
fibers %
basal 24th week
77.6 88.6
83.2 85.9
74.0 77.4
Type Ha
Hypertrophic
fibers %
basal 24th week
0.4 0.9
1.4 4.9
3.3 2.0
Fig. 3. Mean fiber diameter before and after L-camitine treatment. Symbols
are: () basal; (E2) 24th week.
Type lib
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marked rise in free plasma and muscle carnitine and, in conse-
quence, a greater availability of the molecule for muscle oxidative
metabolism, irrespective of the administration route.
The 24-week treatment with L-carnitine seems to have been
responsible for the 7% increase in the diameter of type I and ha
fibers, but to have provoked no appreciable modification in type
lib fibers, which is what would be expected from the metabolic
characteristics of muscle fibers [4—6]. Type I fibers, mainly
oxidative and type ha, which are mixed oxidative-glycolytic, can
utilize fatty acids and so take advantage of carnitine uptake to
produce energy. In contrast, as type hlb fibers are strictly glyco-
lytic, they were not modified by the treatment. The specific trophic
effect of L-carnitine was also confirmed by the fact that all
hematochemical and hemocytometric indices remained unaltered
during treatment, thereby indicating that L-carnitine exerts a
direct effect on muscle.
The increase in the diameter of type I and ha fibers seems to
depend on the reduction in atrophic fibers, since after therapy the
atrophic factor was about half the basal value for both fiber types,
and the percentage of type I atrophic fibers dropped from 22.0%
to 10.5% and that of type ha from 15.3% to 9.1%. When type JIb
fibers were used as an internal control, that is, presuming that
variations in this type of fiber were treatment independent, the
reduction in the proportion of atrophic type I fibers was significant
(P < 0.025), and the decrease in type ha atrophic fibers was at the
limits of significance (P < 0.07). A greater responsiveness of the
more oxidative fiber to L-carnitine could account for this differ-
ence. The increase in fiber diameter together with a reduction of
frequency of atrophic fibers also agrees well with the improved
muscular force.
No significant modifications in the relative percentages of the
different fiber types were documented at the second biopsy. As far
as we know, there is only one other study [13] of muscle
morphometry in dialyzed patients supplemented with L-carnitine.
In that study, after long-term treatment with L-carnitine, Spagnoli
et al found not only type I fiber hypertrophy and regression of
hypertrophy after therapy suspension, but also a significant pre-
dominance of type I fibers, which was presumed to be due to
phenotypic transformation of type ha to type I fibers as a result of
the great availability of lipidic substrates for oxidative metabolism.
A possible explanation for this discrepancy would be that our
treatment was sufficient to obtain a decrease in oxidative fiber
atrophy, but not continued long enough to modify the percentage
of the fibers.
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